Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates-Reference-Cited by-同舟云学术

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

Published:2022-09-26 Issue:1 Volume:11 Page:2229-2247
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Tukhvatulin Amir I.¹^ORCID,Gordeychuk Ilya V.²³^ORCID,Dolzhikova Inna V.¹^ORCID,Dzharullaeva Alina S.¹^ORCID,Krasina Marina E.¹^ORCID,Bayurova Ekaterina O.²^ORCID,Grousova Daria M.¹^ORCID,Kovyrshina Anna V.¹^ORCID,Kondrashova Alla S.²^ORCID,Avdoshina Daria V.²^ORCID,Gulyaev Stanislav A.²^ORCID,Gulyaeva Tatiana V.²^ORCID,Moroz Andrey V.²^ORCID,Illarionova Viktoria V.²^ORCID,Zorkov Ilya D.¹^ORCID,Iliukhina Anna A.¹^ORCID,Shelkov Artem Y.¹^ORCID,Botikov Andrei G.¹^ORCID,Erokhova Alina S.¹^ORCID,Shcheblyakov Dmitry V.¹^ORCID,Esmagambetov Ilias B.¹^ORCID,Zubkova Olga V.¹^ORCID,Tokarskaya Elisaveta A.¹^ORCID,Savina Daria M.¹^ORCID,Vereveyko Yulia R.¹^ORCID,Ungur Anastasiya S.¹^ORCID,Naroditsky Boris S.¹^ORCID,Ishmukhametov Aydar A.²³^ORCID,Logunov Denis Y.¹³^ORCID,Gintsburg Alexander L.¹³^ORCID

Affiliation:

1. Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, Russia

2. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia

3. Sechenov First Moscow State Medical University, Moscow, Russia

Funder

Russain Direct Investment Fund

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2119169

Reference36 articles.

1. Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization. 4–7 April 2022

2. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

3. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges

4. Organisation WH. Strategy to achieve global Covid-19 vaccination by mid-2022. 2021 Oct 6.

5. Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental Use of Common Marmosets (<i>Callithrix jacchus</i>) in Preclinical Trials of Antiviral Vaccines;Acta Naturae;2024-08-21

2. SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity;Vaccines;2024-07-18

3. Exploring the promise of COVID-19 vaccines: A review of preclinical studies;Features, Transmission, Detection, and Case Studies in COVID-19;2024

4. Peptide fibrils as vaccine: a proof of concept;2023-12-30

5. A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation;Frontiers in Immunology;2023-11-02